Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Perspective

Future Perspectives of Wharton’s Jelly Mesenchymal Stem Cells and their Soluble Factors in Radioprotection

Author(s): Dharmendra Kumar Maurya* and Santosh Kumar Sandur

Volume 19, Issue 6, 2024

Published on: 31 January, 2023

Page: [781 - 784] Pages: 4

DOI: 10.2174/1574888X18666230119103905

Price: $65

conference banner
Abstract

Acute radiation syndrome (ARS) is also known as triple syndrome, which develops after whole-body radiation exposure. During unforeseen exposures, these syndromes are set in depending on the dose of radiation. Cell-based therapy, especially using stem cells and their soluble factors, is gaining wide attention in the field of regenerative medicine to treat various diseases, including degenerative diseases. Stem cells attract prime attention because of their profound inherent tissue repair capability and regeneration potential. Further, stem cell therapy can be one of the promising strategies for the amelioration of ARS because of its ability to lodge in damaged tissue and release regenerative cytokines by sensing the local injury. In this regard, human Wharton's jelly-derived mesenchymal stem cells (hWJ-MSCs) have gained substantial attention for their applications in the treatment of various human diseases due to several advantages offered by them. This article is intended to provide future perspective on the use of WJ-MSCs for the management of accidental radiation injury in pre-clinical models, and finally, their utility in regeneration of damaged tissues and organs.

Next »
[1]
Fong CY, Chak LL, Biswas A, et al. Human Wharton’s jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Rev 2011; 7(1): 1-16.
[http://dx.doi.org/10.1007/s12015-010-9166-x] [PMID: 20602182]
[2]
La Rocca G, Anzalone R, Corrao S, et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: Differentiation potential and detection of new markers. Histochem Cell Biol 2009; 131(2): 267-82.
[http://dx.doi.org/10.1007/s00418-008-0519-3] [PMID: 18836737]
[3]
Troyer DL, Weiss ML. Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells 2008; 26(3): 591-9.
[http://dx.doi.org/10.1634/stemcells.2007-0439] [PMID: 18065397]
[4]
Bongso A, Fong CY. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton’s jelly of the human umbilical cord. Stem Cell Rev 2013; 9(2): 226-40.
[http://dx.doi.org/10.1007/s12015-012-9418-z] [PMID: 23233233]
[5]
Prasanna JS, Sowmya Jahnavi V. Wharton’s jelly mesenchymal stem cells as off-the-shelf cellular therapeutics: A closer look into their regenerative and immunomodulatory properties. Open Tissue Eng Regen Med J 2011; 4(1): 28-38.
[6]
Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Pro-inflammatory cytokines, IFN gamma and TNF alpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010; 5(2): e9016.
[http://dx.doi.org/10.1371/journal.pone.0009016] [PMID: 20126406]
[7]
Weiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord Wharton’s jelly-derived cells. Stem Cells 2008; 26(11): 2865-74.
[http://dx.doi.org/10.1634/stemcells.2007-1028] [PMID: 18703664]
[8]
English K, French A, Wood KJ. Mesenchymal stromal cells: Facilitators of successful transplantation? Cell Stem Cell 2010; 7(4): 431-42.
[http://dx.doi.org/10.1016/j.stem.2010.09.009] [PMID: 20887949]
[9]
Can A, Celikkan FT, Cinar O. Umbilical cord mesenchymal stromal cell transplantations: A systemic analysis of clinical trials. Cytotherapy 2017; 19(12): 1351-82.
[http://dx.doi.org/10.1016/j.jcyt.2017.08.004] [PMID: 28964742]
[10]
Doi C, Maurya DK, Pyle MM, Troyer D, Tamura M. Cytotherapy with naive rat umbilical cord matrix stem cells significantly attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic mice. Cytotherapy 2010; 12(3): 408-17.
[http://dx.doi.org/10.3109/14653240903548194] [PMID: 20345214]
[11]
Maurya DK, Doi C, Kawabata A, et al. Therapy with un-engineered naïve rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma. BMC Cancer 2010; 10(1): 590.
[http://dx.doi.org/10.1186/1471-2407-10-590] [PMID: 21029413]
[12]
Ayuzawa R, Doi C, Rachakatla RS, et al. Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett 2009; 280(1): 31-7.
[http://dx.doi.org/10.1016/j.canlet.2009.02.011] [PMID: 19285791]
[13]
Matsuzuka T, Rachakatla RS, Doi C, et al. Human umbilical cord matrix-derived stem cells expressing interferon-β gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. Lung Cancer 2010; 70(1): 28-36.
[http://dx.doi.org/10.1016/j.lungcan.2010.01.003] [PMID: 20138387]
[14]
Zhang X, Xia Y, Ji C. Human umbilical cord blood stem cells applied in therapy for ionizing radiation injury. Integr Mol Med 2015; 2(5): 284-7.
[15]
Kovalenko OA, Azzam EI, Ende N. Human umbilical-cord-blood mononucleated cells enhance the survival of lethally irradiated mice: Dosage and the window of time. J Radiat Res 2013; 54(6): 1010-4.
[http://dx.doi.org/10.1093/jrr/rrt062] [PMID: 23792493]
[16]
Bandekar M, Maurya DK, Sharma D, et al. Xenogeneic transplantation of human WJ‐MSCs rescues mice from acute radiation syndrome via Nrf‐2‐dependent regeneration of damaged tissues. Am J Transplant 2020; 20(8): 2044-57.
[http://dx.doi.org/10.1111/ajt.15819] [PMID: 32040239]
[17]
Maurya DK, Bandekar M, Sandur SK. Soluble factors secreted by human Wharton’s jelly mesenchymal stromal/stem cells exhibit therapeutic radioprotection: A mechanistic study with integrating network biology. World J Stem Cells 2022; 14(5): 347-61.
[http://dx.doi.org/10.4252/wjsc.v14.i5.347] [PMID: 35722198]
[18]
Sun W, Luo L, Feng Y, et al. Aggregation‐induced emission gold clustoluminogens for enhanced low‐Dose X‐ray‐induced photodynamic therapy. Angew Chem Int Ed 2020; 59(25): 9914-21.
[http://dx.doi.org/10.1002/anie.201908712] [PMID: 31418982]
[19]
Zhang C, Zhu Y, Wang J, Hou L, Li W, An H. CXCR4-overexpressing umbilical cord mesenchymal stem cells enhance protection against radiation-induced lung injury. Stem Cells Int 2019; 2019: 1-12.
[http://dx.doi.org/10.1155/2019/2457082] [PMID: 30867667]
[20]
Wang G, Ren X, Yan H, et al. Neuroprotective effects of umbilical cord-derived mesenchymal stem cells on radiation-induced brain injury in mice. Ann Clin Lab Sci 2020; 50(1): 57-64.
[PMID: 32161012]
[21]
Chen ZY, Hu YY, Hu XF, Cheng LX. The conditioned medium of human mesenchymal stromal cells reduces irradiation-induced damage in cardiac fibroblast cells. J Radiat Res 2018; 59(5): 555-64.
[http://dx.doi.org/10.1093/jrr/rry048] [PMID: 30010837]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy